AccessibilityHelpAbout Us
Telix Pharmaceuticals logo

Telix Pharmaceuticals(OTC) TLPPF

Market Cap$3.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+971%
5 Year+143%
1 Year+3%
1 Month+1%
$11.67
-2.34%
-0.28Today
Telix Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 11.672026-09-24
Telix Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.51%USD 12.352026-09-17
1 month+1.21%USD 11.532026-08-25
3 month+16.7%USD 10.002026-06-26
Year to date+50.85%USD 7.742025-12-31
1 year+2.82%USD 11.352025-09-24
3 year+64.37%USD 7.102023-09-25
5 year+143.13%USD 4.802021-09-24
Since inception+970.64%USD 1.092019-07-25

Telix Pharmaceuticals Financials at a Glance

Market Cap

$3.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.50B

Net Income (TTM)

A$81.87M

EPS (TTM)

$0.09

P/E Ratio

118.24

Dividend

$0.00

Beta (Volatility)

0.42 (Low)

Price

$11.67

Volume

1,660

Open

$11.97

Previous Close

$11.67

Daily Range

$11.67 - $11.97

52-Week Range

$5.91 - $13.00

Estimated Earnings Date

Feb 19, 2027

TLPPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, with a strong emphasis on innovative cancer treatments.

Products and Services
  • TLX591: A lutetium-labeled radio antibody-drug conjugate for advanced prostate cancer
  • TLX250: An rADC targeting advanced metastatic kidney cancer
  • Illuccix and Gozellix: Radiopharmaceuticals for prostate cancer treatment
Growth Outlook
  • Recent Phase 3 trials for TLX591 show promising results in prostate cancer
  • Expansion into international markets enhances growth potential
  • Strategic collaborations with leading research institutions support innovation
Financial Highlights
  • Q2 2026 revenue of 678.5 million AUD, a significant increase from previous quarters
  • Net income of 54.5 million AUD in Q2 2026, reflecting strong operational performance
  • Cash and cash equivalents reached 363.1 million AUD, providing financial stability
Telix Pharmaceuticals Limited is positioned in the biotechnology sector, focusing on innovative solutions for cancer treatment. The company's lead product, TLX591, is currently in Phase 3 clinical trials, indicating a strong commitment to advancing cancer therapies. The recent financial performance highlights a robust revenue growth trajectory, with Q2 2026 revenue significantly surpassing previous quarters. The net income of 54.5 million AUD demonstrates effective cost management and operational efficiency. Furthermore, the company's cash reserves of 363.1 million AUD provide a solid foundation for future growth initiatives and research endeavors. With strategic collaborations and a focus on international expansion, Telix Pharmaceuticals is well-positioned to capitalize on emerging opportunities in the biopharmaceutical landscape.
AI Generated • Sep 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,184

CEO

Christian P. Behrenbruch, PhD, EMBA

Website

www.telixpharma.com

Headquarters

North Melbourne, VIC 3051, AU

TLPPF Financials

Key Financial Metrics (TTM)

Gross Margin

52.16%

Operating Margin

-0.73%

Net Income Margin

3.60%

Return on Equity

7.11%

Return on Capital

2.08%

Return on Assets

2.40%

Earnings Yield

0.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

339.89M

Volume

1.66K

Avg. Volume

3.49K

Financials (TTM)

Gross Profit

A$1.36B

Operating Income

A$74.61M

EBITDA

A$132.08M

Operating Cash Flow

A$9.31M

Capital Expenditure

-A$97.55M

Free Cash Flow

-A$82.76M

Cash & ST Invst.

A$363.10M

Total Debt

A$835.81M

Telix Pharmaceuticals Performance Analysis

Telix Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 110,983,5751846.6%
20232023-12-31AUD 333,573,719200.6%
20242024-12-31AUD 516,602,59754.9%
20252025-12-31AUD 803,794,00055.6%
Telix Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31214.5%
Q22025-06-30-0.2%
Q42025-12-316.3%
Q22026-06-307.6%
Telix Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.238.5%
20232023-12-31AUD 0.01N/A
20242024-12-31AUD 0.10791.6%
20252025-12-31AUD -0.02N/A
Telix Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31230.3%
Q22025-06-30-109.4%
Q42025-12-31-110.7%
Q22026-06-30837.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$678.51M

+259.1%

Gross Profit

A$350.00M

+182.5%

Gross Margin

51.58%

N/A

Market Cap

$3.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.35M

N/A

Employees

1,184

N/A

Net Income

A$54.48M

+366.5%

EBITDA

A$16.97M

-57.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$363.10M

+205.5%

Total Debt

A$835.81M

+3674.6%

Accounts Receivable

A$245.60M

+152.5%

Inventory

A$56.26M

+82.6%

Long Term Debt

A$813.58M

+4330.0%

Short Term Debt

A$22.23M

+488.0%

Return on Assets

2.40%

N/A

Return on Invested Capital

-0.59%

N/A

Free Cash Flow

A$5.79M

-70.9%

Operating Cash Flow

A$32.74M

-2.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CAMRFCamurus AB
$61.75+0.00%
SNPHYSanten Pharmaceutical Co., Ltd.
$11.05+2.79%
ANSLFAnsell Limited
$21.64+0.00%
BVNRYBavarian Nordic A/S
$11.04-1.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.54+3.55%
INTCIntel
$123.00-3.45%
NVDANvidia
$225.07+0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.94-3.02%

Questions About TLPPF

What is the current price of Telix Pharmaceuticals?

Telix Pharmaceuticals is trading at $11.67 per share.

What is the 52-week range for Telix Pharmaceuticals?

Over the past 52 weeks, Telix Pharmaceuticals has traded between $5.91 and $13.00.

How much debt does Telix Pharmaceuticals have?

As of the most recent reporting period, Telix Pharmaceuticals reported total debt of A$467.11M.

How much cash does Telix Pharmaceuticals have on hand?

Telix Pharmaceuticals reported A$141.87M in cash and cash equivalents in its most recent financial results.

What is Telix Pharmaceuticals’s dividend yield?

Telix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services